Inhibikase Therapeutics, Inc. (IKT)
NASDAQ: IKT · Real-Time Price · USD
1.620
-0.030 (-1.82%)
At close: Jun 27, 2025, 4:00 PM
1.380
-0.240 (-14.81%)
After-hours: Jun 27, 2025, 5:05 PM EDT
Inhibikase Therapeutics Market Cap
Inhibikase Therapeutics has a market cap or net worth of $120.43 million as of June 27, 2025. Its market cap has increased by 923.89% in one year.
Market Cap
120.43M
Enterprise Value
27.33M
1-Year Change
923.89%
Ranking
Category
Stock Price
$1.62
Market Cap Chart
Since the IPO on December 23, 2020, Inhibikase Therapeutics's market cap has increased from $100.46M to $120.43M, an increase of 19.89%. That is a compound annual growth rate of 4.10%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Jun 26, 2025 | 122.66M | -43.83% |
| Dec 31, 2024 | 218.38M | 2,684.93% |
| Dec 29, 2023 | 7.84M | -37.83% |
| Dec 30, 2022 | 12.61M | -65.89% |
| Dec 31, 2021 | 36.98M | -46.68% |
| Dec 31, 2020 | 69.35M | -30.96% |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Eli Lilly and Company | 713.81B |
| Johnson & Johnson | 365.75B |
| AbbVie | 329.95B |
| Novo Nordisk | 299.93B |
| UnitedHealth Group | 274.52B |
| Novartis AG | 235.02B |
| Abbott Laboratories | 232.56B |
| AstraZeneca | 215.99B |